RT Journal Article
T1 Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients.
A1 Perez-Martinez, Pablo
A1 Alcala-Diaz, Juan F
A1 Kabagambe, Edmon K
A1 Garcia-Rios, Antonio
A1 Tsai, Michael Y
A1 Delgado-Lista, Javier
A1 Kolovou, Genovefa
A1 Straka, Robert J
A1 Gomez-Delgado, Francisco
A1 Hopkins, Paul N
A1 Marin, Carmen
A1 Borecki, Ingrid
A1 Yubero-Serrano, Elena M
A1 Hixson, James E
A1 Camargo, Antonio
A1 Province, Michael A
A1 Lopez-Moreno, Javier
A1 Rodriguez-Cantalejo, Fernando
A1 Tinahones, Francisco J
A1 Mikhailidis, Dimitri P
A1 Perez-Jimenez, Francisco
A1 Arnett, Donna K
A1 Ordovas, Jose M
A1 Lopez-Miranda, Jose
K1 CORDIOPREV study
K1 Coronary heart disease
K1 GOLDN study
K1 Oral-fat tolerance test
K1 Postprandial lipemia
K1 Triglycerides
AB Previous studies have suggested that for clinical purposes, subjects with fasting triglycerides (TGs) between 89-180 mg/dl (1-2 mmol/l) would benefit from postprandial TGs testing. To determine the postprandial TG response in 2 independent studies and validate who should benefit diagnostically from an oral-fat tolerance test (OFTT) in clinical practice. A population of 1002 patients with coronary heart disease (CHD) from the CORDIOPREV clinical trial and 1115 white US subjects from the GOLDN study underwent OFTTs. Subjects were classified into 3 groups according to fasting cut points of TGs to predict the usefulness of OFTT: (1) TG  180 mg/dl (>2 mmol/l). Postprandial TG concentration at any point > 220 mg/dl (>2.5 mmol/l) has been pre-established as an undesirable postprandial response. Of the total, 49% patients with CHD and 42% from the general population showed an undesirable response after the OFTT. The prevalence of undesirable postprandial TG in the CORDIOPREV clinical trial was 12.8, 50.3, and 89.7%, in group 1, 2, and 3, respectively (P  These two studies validate the predictive values reported in a previous consensus. Moreover, the findings of the CORDIOPREV and GOLDN studies show that an OFTT is useful to identify postprandial hyperlipidemia in subjects with fasting TG between 1-2 mmol/l (89-180 mg/dL), because approximately half of them have hidden postprandial hyperlipidemia, which may influence treatment. An OFTT does not provide additional information regarding postprandial hyperlipidemia in subjects with low TG (2 mmol/l, >180 mg/dl).
PB Elsevier
SN 1933-2874
YR 2016
FD 2016-05-25
LK http://hdl.handle.net/10668/10481
UL http://hdl.handle.net/10668/10481
LA en
NO Perez-Martinez P, Alcala-Diaz JF, Kabagambe EK, Garcia-Rios A, Tsai MY, Delgado-Lista J, et al. Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients. J Clin Lipidol. 2016 Sep-Oct;10(5):1163-71
NO We thank the EASP (Escuela Andaluza de Salud Publica), Granada, Spain, which performed the randomi zation process of this study. The ORDIOPREV study is supported by the Funda cion Patrimonio Comunal Olivarero. We also received addi tional funding from CITOLIVA, CEAS, Junta de Andalucia (Consejeria de Salud, Consejeria de Agricultura y Pesca, Consejeria de Innovacion, Ciencia y Empresa), Diputaciones de Jaen y Cordoba, Centro de Excelencia en Investigacion sobre Aceite de Oliva y Salud, and Ministerio de Medio Ambiente, Medio Rural y Marino, Spanish Govern ment. It was also partly supported by research grants from the Ministerio de Ciencia e Innovaciín (AGL2009-122270 to Jose Lopez-Miranda, FIS PI13/00185 to Dr Perez-Martinez, FIS PI13/00023 to Dr Delgado-Lista); Ministerio de economía y Competitividad (AGL2012/39615 to Jose Lopez-Miranda); Proyecto de Excelencia, Consejeria de Economia, Innovaci on, Ciencia y Empleo (CVI-7450 to Jose Lopez-Miranda); by a Research Grant from the European Community (NUTRITECH European Integrated Project-289511). The GOLDN study was supported by NIH Heart,Lung and Blood Institute grant U 01HL72524, Genetic and Environmental Determinants of Tri glycerides. Dr Gomez-Delgado is supported by an ISCIIIresearch contract (Programa Rio-Hortega). The CIBER OBN is an initiative of the Instituto de Salud Carlos III, Madrid, Spain. The authors declare that they have no competing interests. The authors’ responsibilities were as follows, Drs Perez Martinez, Alcala-Diaz, and Jose Lopez-Miranda.: drafted the manuscript and analyzed the data; Drs Ordovas, Delgado-Lista, Kolovou, Kabagambe, Mikhailidis, Perez Jimenez, and Arnett: supervised data analysis, helped interpret the results, and provided critical comments on the manuscript; Garcia-Rios, Tsai, Straka, Gomez-Delgado,Hopkins, Marin, Borecki, Yubero-Serrano, Hixson, Ca margo, Tinahones, Province, Lopez-Moreno, and Rodriguez-Cantalejo provided critical review of the article. All authors read and approved the final manuscript.
DS RISalud
RD Apr 11, 2025